Linked Life Data

3754234

Source:http://linkedlifedata.com/resource/pubmed/id/3754234

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1986-4-29
pubmed:abstractText
Thirty-eight patients with advanced or recurrent squamous cell carcinoma of the vulva no longer amenable to control with surgery and/or radiotherapy were entered onto one of two phase II studies. One was deemed ineligible because of a primary site of origin other than vulva. Of the remaining 37, 13 patients received piperazinedione 9 mg/m2 iv every 3 weeks. No objective regressions were observed. Five patients were judged to have had stable disease, while eight demonstrated increasing disease. The other 24 patients received cisplatin 50 mg/m2 iv every 3 weeks. Of the 22 who were evaluable for response because of the presence of measurable disease, no objective regression of disease was observed. Ten had stable disease, while the remaining 12 had increasing disease. Adverse effects were tolerable for each study agent and were essentially those reported in other series for these two drugs. These results suggest that neither agent is active in advanced or recurrent squamous cell carcinoma of the vulva at least at the dose and schedule tested.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0090-8258
pubmed:author
pubmed:issnType
Print
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
358-63
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
1986
pubmed:articleTitle
Phase II trials of cisplatin and piperazinedione in advanced or recurrent squamous cell carcinoma of the vulva: a Gynecologic Oncology Group Study.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Controlled Clinical Trial